Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Operating Income (2016 - 2025)

IGC Pharma has reported Operating Income over the past 16 years, most recently at -$2.9 million for Q3 2025.

  • Quarterly Operating Income fell 64.72% to -$2.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$8.1 million through Sep 2025, down 258.78% year-over-year, with the annual reading at -$7.4 million for FY2025, 172.75% down from the prior year.
  • Operating Income was -$2.9 million for Q3 2025 at IGC Pharma, down from -$1.9 million in the prior quarter.
  • Over five years, Operating Income peaked at $5.8 million in Q1 2022 and troughed at -$4.3 million in Q3 2021.
  • The 5-year median for Operating Income is -$2.4 million (2021), against an average of -$1.7 million.
  • Year-over-year, Operating Income skyrocketed 306.88% in 2022 and then crashed 169.95% in 2023.
  • A 5-year view of Operating Income shows it stood at -$2.4 million in 2021, then rose by 4.49% to -$2.3 million in 2022, then crashed by 31.61% to -$3.0 million in 2023, then surged by 37.36% to -$1.9 million in 2024, then plummeted by 54.37% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Operating Income are -$2.9 million (Q3 2025), -$1.9 million (Q2 2025), and -$1.4 million (Q1 2025).